Stock Track | Haixi Pharma Soars 5.74% Intraday on Strong Annual Results and Broker Buy Rating

Stock Track05-05 09:42

Haixi Pharma's stock surged 5.74% during intraday trading on Tuesday, marking a significant rebound.

The sharp rise follows the company's release of its annual report, which showed revenue of RMB 582 million, a 24.79% year-over-year increase, and net profit attributable to shareholders of RMB 177 million, up 30.09%. Concurrently, Huayuan Securities initiated coverage on the stock with a Buy rating, emphasizing the firm's transition into an integrated generic and innovative pharmaceutical company. The broker highlighted the potential of its innovative drug candidate HXP056, a potentially first-in-class oral treatment for wAMD/DME/RVO, which could unlock substantial mid-to-long term valuation upside given the absence of approved oral treatments for wAMD globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185030166?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 09:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185030166","market":"nz","top_or_hot":-1,"title":"Stock Track | Haixi Pharma Soars 5.74% Intraday on Strong Annual Results and Broker Buy Rating","media":"Stock Track","content":"<p>Haixi Pharma's stock surged 5.74% during intraday trading on Tuesday, marking a significant rebound.</p><p>The sharp rise follows the company's release of its annual report, which showed revenue of RMB 582 million, a 24.79% year-over-year increase, and net profit attributable to shareholders of RMB 177 million, up 30.09%. Concurrently, Huayuan Securities initiated coverage on the stock with a Buy rating, emphasizing the firm's transition into an integrated generic and innovative pharmaceutical company. The broker highlighted the potential of its innovative drug candidate HXP056, a potentially first-in-class oral treatment for wAMD/DME/RVO, which could unlock substantial mid-to-long term valuation upside given the absence of approved oral treatments for wAMD globally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Haixi Pharma Soars 5.74% Intraday on Strong Annual Results and Broker Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Haixi Pharma Soars 5.74% Intraday on Strong Annual Results and Broker Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-05 09:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haixi Pharma's stock surged 5.74% during intraday trading on Tuesday, marking a significant rebound.</p><p>The sharp rise follows the company's release of its annual report, which showed revenue of RMB 582 million, a 24.79% year-over-year increase, and net profit attributable to shareholders of RMB 177 million, up 30.09%. Concurrently, Huayuan Securities initiated coverage on the stock with a Buy rating, emphasizing the firm's transition into an integrated generic and innovative pharmaceutical company. The broker highlighted the potential of its innovative drug candidate HXP056, a potentially first-in-class oral treatment for wAMD/DME/RVO, which could unlock substantial mid-to-long term valuation upside given the absence of approved oral treatments for wAMD globally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1185030166","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185030166","pubTimestamp":1777945362,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Haixi Pharma's stock surged 5.74% during intraday trading on Tuesday, marking a significant rebound.The sharp rise follows the company's release of its annual report, which showed revenue of RMB 582...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"个股赛道|海西药业盘中大涨5.74%年报业绩强劲券商买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Haixi Pharma's stock surged 5.74% during intraday trading on Tuesday, marking a significant rebound.The sharp rise follows the company's release of its annual report, which showed revenue of RMB 582 million, a 24.79% year-over-year increase, and net profit attributable to shareholders of RMB 177 million, up 30.09%. Concurrently, Huayuan Securities initiated coverage on the stock with a Buy rating, emphasizing the firm's transition into an integrated generic and innovative pharmaceutical company. The broker highlighted the potential of its innovative drug candidate HXP056, a potentially first-in-class oral treatment for wAMD/DME/RVO, which could unlock substantial mid-to-long term valuation upside given the absence of approved oral treatments for wAMD globally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185030166","isCrawlerRequest":true}